Last updated: 2026-09-21 01:33:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Hemab Therapeutics Holdings, Inc. (COAG) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $41,18, with a market capitalization of $1,92B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $23,00 to $55,42. This page covers its latest market performance, valuation, price trends and company information.
$1,92B | |
$41,67 | |
$55,42 | |
$23,00 | |
$41,22 | |
586,56K | |
426,76K | |
-- | |
$55,42 | |
$23,00 | |
-- | |
-- |
Hemab Therapeutics Holdings, Inc. (COAG) last closed at $41,22 as of 2026-09-18 23:31:00, unchanged from the previous close of $41,22.
During the latest regular trading session, COAG traded between $23,00 and $55,42, with a volume of 586,56K shares. The closing price was near the middle and near the middle of its 52-week range.
Over the past seven days, Hemab Therapeutics Holdings, Inc. (COAG) moved from $39,88 to $41,18, representing a gain of 3,26% ($1,30).
The stock traded between $38,79 and $44,52 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 961,97 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 56,1%
COAG is currently trading at $41,18, placing it 56,1% of the way from its 52-week low of $23,00 to its 52-week high of $55,42. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Hemab Therapeutics Holdings, Inc. (COAG) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.